Business Model Breakdown
How Immatics NV Makes Money
IMTX
Market Cap
$1.5B
Profit Margin
-407.0%
The Short Version
Immatics NV is a clinical-stage biotechnology company developing advanced T-cell receptor (TCR) engineered T cell immunotherapies and bispecifics to treat various solid tumors. They utilize their proprietary XPRESIDENT platform to discover novel, intracellular tumor targets, which are often inaccessible to conventional therapies, and then engineer highly specific T-cells or bispecific molecules to attack these targets. The company generates revenue primarily through collaboration agreements, milestone payments, and research funding from pharmaceutical partners as they advance their pipeline programs.
Where the Revenue Comes From
Collaboration revenue (milestone payments, research funding) (~100% of current revenue)
Potential future product sales (post-commercialization)
Who buys: Currently, large pharmaceutical partners (e.g., Bristol Myers Squibb). In the future, oncologists and patients globally for their therapeutic products.
Why It Works (Competitive Advantages)
- ✔Proprietary XPRESIDENT platform for identifying novel intracellular targets.
- ✔Validated by significant partnership with Bristol Myers Squibb (BMS).
- ✔Diverse pipeline of TCR-T cell therapies and bispecifics.
Economic Moat: Narrow (Intangible Assets/IP (proprietary XPRESIDENT platform, extensive TCR library, specific target identification), Switching Costs (high cost and time for competitors to replicate clinical development in specialized cell therapy))
What Our Analysis Says
DVR Score as of May 6, 2026
Immatics NV retains significant 10x growth potential, driven by its proprietary XPRESIDENT platform and pipeline of PRAME-targeted TCR-T cell therapies and bispecifics addressing vast unmet needs in solid tumors. The recent Q4 2025 earnings beat and acceptance of four oral presentations at ASCO 2026 provide positive validation and strong near-term catalysts. The BMS partnership remains a key asset. While financial health reflects typical clinical-stage biotech (unprofitable with significant cash burn), clinical progress and positive analyst sentiment (new 'Buy' initiations) balance the inherent development and regulatory risks. Future capital raises will be critical, carrying potential for dilution.